Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “NRAS Gene Mutation Negative”

13 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 13 of 13 results

Early research (Phase 1)Study completedNCT02065063
What this trial is testing

Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors

Who this might be right for
Cancer
GlaxoSmithKline 28
Early research (Phase 1)Ended earlyNCT02199223
What this trial is testing

Regorafenib + Panitumumab for Colorectal Cancers

Who this might be right for
KRAS and NRAS Wild-type Colorectal Cancer
University of Utah 2
Testing effectiveness (Phase 2)Study completedNCT02399943
What this trial is testing

A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer

Who this might be right for
Colorectal CancerKRAS WildtypeNRAS Wildtype+1 more
University Health Network, Toronto 14
Large-scale testing (Phase 3)Study completedNCT02394795
What this trial is testing

Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC

Who this might be right for
Colorectal Cancer
Takeda 823
Testing effectiveness (Phase 2)Study completedNCT04059224
What this trial is testing

TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma

Who this might be right for
Stage IV MelanomaStage III Melanoma
Universitair Ziekenhuis Brussel 45
Testing effectiveness (Phase 2)Active Not RecruitingNCT04117945
What this trial is testing

Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

Who this might be right for
BRAF V600E NegativeKRAS Gene Mutation NegativeLocally Advanced Unresectable Colorectal Adenocarcinoma+10 more
Academic and Community Cancer Research United 22
Testing effectiveness (Phase 2)Ended earlyNCT01925274
What this trial is testing

PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Pfizer 19
Testing effectiveness (Phase 2)Study completedNCT01814501
What this trial is testing

Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab

Who this might be right for
Mucinous Adenocarcinoma of the ColonMucinous Adenocarcinoma of the RectumRecurrent Colon Cancer+5 more
John Hays 16
Not applicableStudy completedNCT02322736
What this trial is testing

Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORR

Who this might be right for
Metastatic Colorectal Cancer
Amgen 218
Not applicableStudy completedNCT03914170
What this trial is testing

Folfirinox + Cetuximab Chemotherapy, in First Line, With Wild RAS and According to BRAF Status in Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer
Institut du Cancer de Montpellier - Val d'Aurelle 70
Testing effectiveness (Phase 2)Ended earlyNCT02587650
What this trial is testing

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

Who this might be right for
ALK Fusion Protein ExpressionBRAF wt AlleleInvasive Skin Melanoma+12 more
University of California, San Francisco 1
Testing effectiveness (Phase 2)Ended earlyNCT03580382
What this trial is testing

Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma

Who this might be right for
Melanoma
NYU Langone Health 3
Testing effectiveness (Phase 2)Study completedNCT02613221
What this trial is testing

A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer

Who this might be right for
Colorectal Cancer
Takeda 56